Status:
UNKNOWN
Hesperidin and Diosmin for Treatment of COVID-19
Lead Sponsor:
Tanta University
Conditions:
Coronavirus Infection
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
SARS-CoV-2 or COVID-19 is representing the major global burden that implicated more than 10 million infected cases and 500 thousand deaths worldwide. The prevalence of this pandemic disease is expecte...
Detailed Description
Research Background and Rationale At the end of December 2019, pneumonia of unknown origin was detected in the hospitals of Wuhan city, China, and reported to the WHO country office for the first time...
Eligibility Criteria
Inclusion
- Confirmed cases of Covid-19 (all by RT-PCR) Newly diagnosed asymptomatic or with upper respiratory tract infection (URTI) patients who will present with rhinitis, pharyngitis, or isolated low-grade fever and myalgia, Adult (18-65 Years old) Both sexes
Exclusion
- Patients with bleeding disorders Patients with low to very low blood pressure Patients after surgery Immunocompromised patients taking medication upon screening
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04452799
Start Date
July 1 2020
End Date
October 30 2020
Last Update
June 30 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.